Hims vs Hers vs Ro vs Found: GLP-1 Telehealth Compared (2026)
Hims, Hers, Ro, and Found are the four most-searched names in the GLP-1 telehealth category. They overlap in product (compounded and brand-name semaglutide and tirzepatide), but they differ meaningfully in audience, pricing structure, coaching depth, and how aggressively they pursue insurance for brand-name medications. This four-way comparison lays the differences out side-by-side so you can match the right operator to your situation.
Hims
Publicly traded telehealth giant with weight-loss, ED, and hair-loss programs under one roof.
Hers
Women-focused sister brand to Hims spanning GLP-1, hair, skincare, and menopause care.
Ro
Mainstream telehealth giant with FDA-approved GLP-1s, an insurance concierge, and prepay savings.
Found
GLP-1 platform that pairs medication with one-on-one coaching and a broad off-label formulary.
| Attribute | Hims | Hers | Ro | Found |
|---|---|---|---|---|
| Primary Audience | Men 18+ | Women 18+ | Adults 18+ | Adults 18+ |
| Lowest Monthly Plan | From $149/mo | From $149/mo | From $99/mo | From $129/mo |
| Compounded GLP-1 | Semaglutide (incl. oral) | Semaglutide (incl. oral) + tirzepatide | Semaglutide + tirzepatide | Semaglutide + tirzepatide |
| FDA Brand-Name GLP-1 Access | Wegovy, Zepbound, Ozempic, Mounjaro | Wegovy, Zepbound, Ozempic, Mounjaro | Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda | Wegovy, Zepbound, Ozempic, Rybelsus, Saxenda, Trulicity, Victoza |
| Insurance Navigation | Limited | Limited | Yes — dedicated team | Yes — dedicated team |
| 1:1 Coaching | No | No | Optional add-on | Yes — included on Rx path |
| Adjacent Categories | ED, hair, mental health, primary care | Menopause, hair, skincare, sexual wellness | ED (Ro Sparks, Daily Rise), hair, primary care | GLP-1 only — with off-label adjuncts (metformin, bupropion-naltrexone) |
| Cancellation Terms | Month-to-month | Month-to-month | Month-to-month | $99 early-cancellation fee inside initial term |
| Public Company | Yes (NYSE: HIMS) | Yes (NYSE: HIMS) | No (private) | No (private) |
| Editor Score | 4.5 / 5 | 4.4 / 5 | 4.6 / 5 | 4.2 / 5 |
What the Studies Actually Show
Pricing reflects publicly listed self-pay rates as of 2026. Insurance acceptance varies by employer plan and pharmacy benefit manager; Ro and Found publish coverage tools but cannot guarantee approval. Compounded GLP-1 availability is governed by the FDA's personalisation exception following the 2024 ruling that ended the official semaglutide and tirzepatide shortages — reputable providers document a clinical justification (custom dose, B12 addition, documented intolerance) on every compounded prescription.
| Endpoint | Hims | Hers | Ro | Found |
|---|---|---|---|---|
| Mean weight loss for the underlying medications1 | Compounded & brand-name semaglutide track Wegovy at −14.9% over 68 weeks (2.4 mg) Compounded GLP-1 has not itself been studied in randomized trials; efficacy is inferred from the active ingredient. The FDA does not formally approve compounded products, so quality depends on the 503A or 503B pharmacy that produces them. | Compounded & brand-name semaglutide and tirzepatide track Wegovy −14.9% / Zepbound −20.9% (15 mg, 72 weeks) | Compounded & brand-name semaglutide and tirzepatide track Wegovy −14.9% / Zepbound −20.9% (15 mg, 72 weeks) | Compounded & brand-name semaglutide and tirzepatide track Wegovy −14.9% / Zepbound −20.9% (15 mg, 72 weeks) |
| GI side effects (per FDA prescribing information)2 | Same active-ingredient profile: nausea, diarrhea, vomiting, constipation ≥5% | Same active-ingredient profile: nausea, diarrhea, vomiting, constipation ≥5% | Same active-ingredient profile: nausea, diarrhea, vomiting, constipation ≥5% | Same active-ingredient profile: nausea, diarrhea, vomiting, constipation ≥5% |
| Cardiovascular outcomes evidence (semaglutide 2.4 mg)4 | SELECT trial: 20% MACE risk reduction in adults with established CV disease and overweight/obesity | SELECT trial: 20% MACE risk reduction | SELECT trial: 20% MACE risk reduction | SELECT trial: 20% MACE risk reduction |
| Behavioral / coaching evidence5 | Not a coaching product; medication-only model | Not a coaching product; medication-only model | Optional coaching add-on; not a core service | Coaching included on Rx path — the Diabetes Prevention Program model shows coaching plus medication outperforms medication alone for sustained weight loss |
The Verdict
If you want the broadest single-account telehealth coverage and you are male, Hims is the natural pick — GLP-1 plus ED, hair, mental health, and primary-care add-ons under one login. Hers is the equivalent for women, with menopause and sexual-wellness coverage layered on top of GLP-1.
If insurance coverage for brand-name Wegovy or Zepbound is the deciding factor, Ro has the deepest insurance-navigation operation in the category and is the only platform here that offers Ro Sparks (compounded tadalafil) and a sizable in-house pharmacy backbone. Expect higher monthly cost, but materially better odds of getting brand-name medication covered.
If you want behavior-change coaching paired with medication, Found is the only one of the four that builds one-on-one coaching into the core subscription rather than treating it as an upsell. The trade-offs are a confusing multi-tier price ladder and a $99 early-cancellation fee — read the terms before committing.
Frequently Asked Questions
Hims vs Hers — are they actually different services?
Same parent company (Hims & Hers Health, NYSE: HIMS), separate audiences and formularies. Hims targets men with GLP-1, ED, hair, and mental health; Hers targets women with GLP-1, menopause, hair, skincare, and sexual wellness. Pricing structure and pharmacy infrastructure are essentially identical.
Which one is cheapest for compounded GLP-1?
Found's Rx path starts at $129/mo, the lowest of the four for the medication-plus-coaching bundle. Ro starts at $99/mo for the core membership, but the medication is billed separately. Hims and Hers both start at $149/mo for compounded GLP-1 inclusive of provider visits.
Which one has the best odds of getting brand-name Wegovy or Zepbound covered by insurance?
Ro and Found both run dedicated insurance-navigation teams. Ro's coverage tool is the most-used in the category; Found has a similar capability but a narrower formulary. Hims and Hers do not aggressively pursue insurance — brand-name medications are billed at manufacturer list price.
Which one offers the broadest formulary beyond GLP-1?
Found is the most narrow (GLP-1 plus a small set of off-label oral adjuncts). Ro covers GLP-1, ED, hair loss, and primary care. Hims and Hers each offer the widest set within their respective audience (men's vs women's health), spanning four to five categories.
Are compounded GLP-1s legal at any of these four?
Yes — compounded GLP-1s remain legal under the FDA's personalisation exception. After the 2024 ruling that ended the official tirzepatide and semaglutide shortages, compounding is permitted only when a licensed clinician documents a clinical justification, such as a customised dose, B12 addition, or a documented allergy to an inactive ingredient in the brand-name product. All four providers operate within this framework.
- STEP 1 Trial — NEJM 2021 \u00b7 Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989–1002.
- FDA Prescribing Information — Wegovy (semaglutide) \u00b7 WEGOVY (semaglutide) injection, for subcutaneous use. U.S. Food and Drug Administration prescribing information.
- SURMOUNT-1 Trial — NEJM 2022 \u00b7 Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216.
- SELECT Trial — NEJM 2023 \u00b7 Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221–2232.
- Diabetes Prevention Program (DPP) — NEJM 2002 / 10-year follow-up Lancet 2009 \u00b7 Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403.
- FDA — Compounding and the FDA: Questions and Answers \u00b7 U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers (last updated 2024). Includes guidance on personalisation exception following the end of the semaglutide and tirzepatide shortages.
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.